(Reuters) -British drugmaker GSK mentioned on Monday that it might pay up to $1.15 billion to purchase Boston-based biopharmaceutical agency IDRx, which is growing a remedy for a uncommon kind of tumour.

IDRx, a privately held biotechnology agency, is growing a remedy for the remedy of gastrointestinal stromal tumours.

The deal, which contains an upfront cost of $1 billion, will add to GSK’s rising portfolio in gastrointestinal cancers.

The British drugmaker, which has been grappling with a decline in its vaccines companies, has stepped up its efforts in most cancers remedy in recent times.

“This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products,” GSK’s Chief Business Officer, Luke Miels, mentioned in a press release.